Welcome to our virtual exhibit booth!


About Us

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. www.karyopharm.com


Contact Us

Elaine Pavlick
(410) 212-8700
Hematology/Oncology Specialist
Karyopharm Therapeutics Inc.